Galapagos and CHDI Foundation, Inc. enter new five-year collaboration for Huntington's disease therapeutics

30-Apr-2010 - Belgium

Galapagos NV and CHDI Foundation, Inc. announced today a new five-year collaboration focused on discovering novel drugs for Huntington's disease. Galapagos' service division BioFocus will perform the research and is eligible to receive US$41 million (€31 million) in research fees during the five-year collaboration.

BioFocus will apply its full range of integrated drug discovery services for this program. Integrated biology and chemistry capabilities will be supported by BioFocus' expertise in complex primary neuronal assay development, high-content screening, fragment-based screening, computational chemistry, ADME/PK and protein crystallography. The new agreement announced today continues and expands the collaboration started in August 2005.

"Having collaborated with CHDI since 2005 in therapeutic target discovery, we are eager to continue working together to develop novel therapies for Huntington's disease and meet this urgent medical need," said Onno van de Stolpe, CEO of Galapagos. "We are confident that the next five years of this long-standing relationship with CHDI will be as productive as the first five."

"BioFocus has delivered expert technologies and experienced staff to therapeutic target and drug discovery research in the fight against Huntington's disease," said Ignacio Munoz-Sanjuan, Vice-President, Biology at CHDI. "This has encouraged us to extend and expand the collaboration, with the ultimate goal of finding disease-modifying treatments for Huntington's."

Other news from the department business & finance

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

First-in-class immunotherapies for the treatment of cancer and autoimmune diseases - ImmunOs Therapeutics Raises $74 Million Series B Financing Round

First-in-class immunotherapies for the treatment of cancer and autoimmune diseases - ImmunOs Therapeutics Raises $74 Million Series B Financing Round

BioMed X and Boehringer Ingelheim start new joint research group

Nobilon advances first vaccine into human trials - Intranasal influenza vaccine begins Phase I clinical development

Raptor Pharmaceuticals and TorreyPines Therapeutics Receive Stockholder Approvals to Merge - Merger to Create NASDAQ-Listed Biopharmaceutical Company named Raptor Pharmaceutical Corp.

Nobel Prize for Physiology or Medicine 2020 Announced - Nobel Prize awarded to Harvey J. Alter, Michael Houghton and Charles M. Rice for the discovery of Hepatitis C virus

Nobel Prize for Physiology or Medicine 2020 Announced - Nobel Prize awarded to Harvey J. Alter, Michael Houghton and Charles M. Rice for the discovery of Hepatitis C virus

PharmAthene and SIGA Technologies sign definitive merger agreement

PerkinElmer announces third quarter results - GAAP Revenue of $548 million versus $563 million in the comparable prior period

Glox Therapeutics Secures £4.3M Seed Funding to Develop Precision Antimicrobials Targeting Drug-resistant Bacteria - Spin-out from the Universities of Glasgow and Oxford

Glox Therapeutics Secures £4.3M Seed Funding to Develop Precision Antimicrobials Targeting Drug-resistant Bacteria - Spin-out from the Universities of Glasgow and Oxford

Doped by food - Dopamine release regulates our eating behaviour

Doped by food - Dopamine release regulates our eating behaviour

Turning fallen leaves into sustainably made paper - Ukrainian scientist selected as a finalist for the Young Inventors Prize 2024

Turning fallen leaves into sustainably made paper - Ukrainian scientist selected as a finalist for the Young Inventors Prize 2024

Merck Celebrates Topping-Out Ceremony for New Membrane Production Plant - Investment of more than € 140 million creates approximately 55 new jobs

Merck Celebrates Topping-Out Ceremony for New Membrane Production Plant - Investment of more than € 140 million creates approximately 55 new jobs

Orikine Bio secures €800k in innovation research funding to advance groundbreaking autoimmune disease therapy - Orikine Bio’s technology platform is on the cusp of revolutionizing the future of immunotherapy

Orikine Bio secures €800k in innovation research funding to advance groundbreaking autoimmune disease therapy - Orikine Bio’s technology platform is on the cusp of revolutionizing the future of immunotherapy